Drug Profile
S 525606
Alternative Names: cedar pollen allergy immunotherapy - Stallergenes/Shionogi; Cedar pollen sublingual immunotherapy; S-525606; STAGR 120Latest Information Update: 08 Sep 2021
Price :
$50
*
At a glance
- Originator Stallergenes SA
- Developer Shionogi; Stallergenes Greer plc
- Class Allergens; Antiallergics; Japanese cedar pollen allergy immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Allergic rhinitis
Most Recent Events
- 08 Sep 2021 Discontinued - Phase-II for Allergic rhinitis in Japan (Sublingual) (Shionogi pipeline, September 2021)
- 18 Oct 2018 S 525606 is still in phase II trials for Allergic rhinitis in Japan (Shionogi pipeline, October 2018)
- 03 Aug 2015 Phase-II clinical trials in Allergic rhinitis in Japan (Sublingual)